Evicenter
P&T meetings

Atebrioz (zilurgisertib)

Fibrodysplasia ossificans progressiva

Also known as INCB000928
Regulatory submission
NDA submitted by May 2026
Last updated
96 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology

Incidence of Fibrodysplasia ossificans progressiva

2 evidence topics · 1 source

Birth frequency derived from the French national prevalence estimate

“Through this method, the prevalence of FOP is estimated to be 1.36 per million inhabitants (or 1/735,000 births).” (opens the source at this quote in a new tab)

Detectability before birth and effect of paternal age on future incidence

“Another question is whether FOP prevalence may rise due to the trend toward an increased paternal age, a known risk factor for FOP as for other conditions due to single-mutation variation” (opens the source at this quote in a new tab)

“FOP is rarely detectable in utero.” (opens the source at this quote in a new tab)

Population-based annual incidence

No evidence found.